Clinical trial NCT06012097: Impact of Gel Aromatherapy on Pain for Patients With De Quervain Disease
Official title: Impact of Gel Aromatherapy on Pain for Patients With De Quervain Disease : Monocentric Study, Controlled, Randomized, Partially Blinded, in Paralleled Groups
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE4
Conditions: De Quervain Disease
Lead sponsor: University Hospital, Strasbourg, France
Sponsor class: OTHER
First posted: 2023-08-25
Enrollment: 70
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: De Quervain disease is characterized by an adductor pollicis longus and extensor pollicis brevis tendons inflammation as thys pass beneath the extensor retinaculum at the radial styloid. This pathology is recognized as a musculoskeletal disorder of the upper limb triggering functional deficits resulting to possible modifications in the professional activity, sources of absenteeism, thus constituting an economic cost for society. At the etiological level, this pathology also affects young mothers (it's called "mother's wrist" or mommy thumb"), mobile phone users ("textonite", "Blackberryte") or video game players ("Nintendoite").

Currently, the treatment is mainly conservative by splint and anti-inflammatory gel and/or corticosteroid infiltration. Howewer, these therapies have undesirable effects. The interest of this study is therefore to propose another therapy based on aromatherapy gel.


Eligibility criteria: Inclusion Criteria:

* Male or female patient aged 18 to 75,
* Patient with unilateral De Quervain's tenosynovitis,
* Patient cared in the Hand Surgery Department, SOS Mains Emergency Department or Rheumatology Department of Strasbourg University Hospitals,
* Patient informed of the results of the prior medical examination,
* Informed consent signed by the patient,
* Patient affiliated to a health insurance social protection scheme or beneficiary,
* For a woman of childbearing potential, negative urine pregnancy test at the inclusion visit and maintenance of effective contraception throughout the study.

Exclusion Criteria:

* Pregnant or breastfeeding patient,
* Patient allergic to a component of the gel with essential oils, Dicloflenac®, NSAIDs, or one of the excipients
* Patient treated with oral non-steroidal anti-inflammatory drugs
* Patient with ongoing treatment with another ointment at the treatment application site (radial edge of the wrist)
* Patient with damaged skin, whatever the lesion: oozing dermatosis, eczema, infected lesion, burn or wound,
* Patient with atopic skin disease,
* Patient with epilepsy or with a history of epilepsy,
* Patient with a history of homolateral De Quervain's tenosynovitis, or having already had corticosteroid infiltrations in the 6 months before his inclusion on the ipsilateral side of the pathology,
* Patient with associated tendinopathies in the elbow or forearm region,
* Impossibility of giving the patient information (patient in an emergency situation, patient with difficulties of understandin, agitation of the patient),
* Patient under legal protection, under guardianship or curatorship.

Primary outcomes:
measure: Measure of pain during the WHAT test
timeFrame: Day 0
measure: Measure of pain during the WHAT test
timeFrame: Day 42
measure: Measure of pain during the WHAT test
timeFrame: Day 84
Secondary outcomes:
Other outcomes:
Locations:
city: Strasbourg
country: France
facility: Service SOS Main
Study officials:
References: